Serina Therapeutics (SER)Director bought ~$2K

~$2K

Approx. value · 1,000 sh @ $2.03

1,000

Holds after · shares reported

Traded

Jul 7, 2026

Filed

Jul 9, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 14, 2026Company filing · Form 8-K · ResultsReported its results
2. May 19, 2026Insider · First insider buy since Dec 2024Director purchased ~$20K of SER shares in the open market
3. May 21, 2026Insider · Their first buy on recordDirector purchased ~$18K of SER shares in the open market
4. May 22, 2026Insider · 2 peopleInsiders: 2 purchases (~$20K)
5. Jun 11, 2026InsiderDirector purchased ~$8.9K of SER shares in the open market
6. Jun 12, 2026InsiderDirector purchased ~$8.8K of SER shares in the open market
7. Jun 17, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
8. Jul 7, 2026 · this disclosureInsider · Bought outside the usual windowDirector purchased ~$2K of SER shares in the open market

What came next

1. Jul 19, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 19, 2026, Serina Therapeutics, Inc. (the “Company”), together with its subsidiary Serina Therapeutics (AL), Inc., entered into an Amended and Restated Employment Agreement (the “A&R Employment Agreement”) with Steve Ledger, the Company’s Chief Executive Officer.”
2. Jul 22, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 22, 2026, Serina Therapeutics, Inc. (the “Company”) issued a press release announcing the appointment of Farrell Simon, Pharm. D., to the Company’s Board of Directors, effective July 22, 2026.”
3. Aug 13, 2026Company filing · Form 8-K · ResultsReported its results
4. Aug 21, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
5. Oct 5, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Serina Therapeutics

OQRO holds no insider, Congress, fund or contract record for Serina Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SER page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Serina Therapeutics

• SEC Form 4Jun 22, 2026
• SEC Form 4Jun 15, 2026
• SEC Form 4Jun 15, 2026
• SEC Form 4May 26, 2026
• SEC Form 4May 26, 2026
• SEC Form 4May 22, 2026

Everything OQRO holds on this company is on its SER page.